Search

Displaying results 551 - 560 of 9667 in total
  1. Drug

    Golimumab

    go.drugbank.com/drugs/DB06674
    ApprovedInvestigational

    treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe … Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate

    Products: SIMPONI 50MG ILO I E FER, SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML
  2. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    It presents selectivity against the mutant forms of EGFR compared to the wild-type. … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

    Products: ALUNBRIG FILM-COATED TABLET 180mg, Alunbrig (Brigatinib) 180mg Film-Coated Tablet
  3. Drug

    Ichthammol

    go.drugbank.com/drugs/DB11341
    Approved

    It is available in OTC products as an active ingredient for the treatment of skin disorders such as eczema, psoriasis and boils as it is thought to exhibit anti-inflammatory, antibacterial and antimycotic … Ichthammol is also referred to as ammonium bituminosulfonate or ammonium bituminosulphonate.

    Products: ITTIOLO BIO CHEM, İHTİYOL ES HEALTH PHARMA % 10 MERHEM, 20 G
  4. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. … [A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]

    Mixtures: ATMADISC 25UG/125UG, PMS-fluticasone Propionate/salmeterol DpiProducts: Serevent- Aem 25mcg/aem, SOLTEL 25UG/SPRUEHSTOSS
  5. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050 … Linagliptin was approved by the FDA on May 2, 2011[L9557].

    Mixtures: Glyxambi Film-Coated Tablets 10mg/5mg, GLYXAMBI 10MG/5 MG FİLM KAPLI TABLET, 30 TABLETProducts: LINAGLIPTIN EG, TRAJENTA DUO 2.5MG/1000MG FILM KAPLI TABLET, 60 ADET
  6. Drug

    Mepivacaine

    go.drugbank.com/drugs/DB00961
    ApprovedInvestigationalVet approved

    It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route.

    Mixtures: MEPISEAL-EProducts: Carbocaine Inj Liq 10mg/ml, Carbocaine Inj Liq 20mg/ml
  7. Drug

    Gefitinib

    go.drugbank.com/drugs/DB00317
    ApprovedInvestigational

    Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

    Products: GEFITINIB EG, IRESSA 250MG
  8. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    Notably, sofosbuvir has come under intense scrutiny since its release to market in 2013. With the price per pill set at $1000, a 12-week treatment can cost upwards of $84,000 per patient [A19636]. … As a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective

    Mixtures: VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG, EPCLUSA TABLET 400MG/100MGProducts: SOVALDI TABLET 400MG, VIRSO Sofosbuvir Tablets 400mg
  9. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.

    Products: TALZENNA CAPSULE 1MG, Talzenna 1mg Hard Capsules
  10. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    [A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific … RET-driven cancer indications.

    Categories: Rearranged during Transfection (RET) InhibitorsProducts: RETSEVMO ® 40MG